Fusion Pharmaceuticals(FUSN) - 2024 Q1 - Quarterly Results

Corporate Update Exhibit 99.1 Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca for total transaction value of up to $2.4 billion; transaction expected to close in the second quarter of 2024 HAMILTON, ON and BOSTON, MA May 7, 2024 /PRNewswire/ -- Fusion Pharm ...